Difference between revisions of "FDG-PET Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
m (Recent Meetings / Call Summaries)
 
(237 intermediate revisions by 9 users not shown)
Line 1: Line 1:
== Quantitative FDG-PET Technical Committee Mission ==
+
{{TOCright}}
  
*'''Mission; Foster adoption of ...'''
+
:Co-chairs: Nathan C. Hall, MD, PhD; John Sunderland, PhD; Jeffrey T. Yap, PhD
**pragmatic and cost effective standards for
+
:RSNA Staff Support: Julie Lisiecki
**accurate and reproducible
+
* [http://tinyurl.com/QIBA-FDG-PET-Roster Roster]
**longitudinal
+
 
**quantitation of
+
== Quantitative FDG-PET Biomarker Committee Mission ==
**biologic parameters
+
 
**with clinical relevance
+
'''Mission: Foster adoption of''' pragmatic and cost effective standards for accurate and reproducible longitudinal quantitation of biologic parameters with clinical relevance and known sigma
**and known sigma
+
  
 
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]
 
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]
  
==Meetings / Call Summaries==
+
 
*[[Monthly FDG-PET Call Summaries]]
+
==Recent Meetings / Call Summaries==
 +
 
 +
*[[Media:11 05 2021 QIBA FDG-PET BC Update Summary-FINAL.pdf|November 5, 2021]]
 +
*[[Media:10 04 2021 QIBA FDG-PET BC Update Summary-FINAL.pdf|October 4, 2021]]
 +
 
 +
*[[Media:05 15 2020 QIBA FDG-PET BC Update Summary-FINAL.pdf|May 15, 2020]]
 +
*[[Media:02 21 2020 QIBA FDG-PET BC Update Summary-FINAL.pdf|February 21, 2020]]
 +
*[[Media:01 17 2020 QIBA FDG-PET BC Update Summary-FINAL.pdf|January 17, 2020]]
 +
 
 +
 
 +
 
 +
'''''[[FDG-PET Call Summaries Archive]]'''''
 +
 
 +
==Nuclear Medicine Combined Biomarker Committee Calls for FDG-PET, Amyloid, SPECT==
 +
 
 +
*[[Combined Nuclear Medicine Biomarker Committee Call Summaries]]
 +
 
  
 
==Profile Development==
 
==Profile Development==
Drafting:
+
'''<font color=green>Technically Confirmed Profile and Supporting Documents:</font>
* [[Media: Profile_FDG-PET_03052011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 03-05-2011''
+
*[[Media: QIBA_FDG-PET_Profile_v112.doc|Technically Confirmed QIBA FDG-PET Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy v112]] ''November 14, 2016''
Archive:
+
*[[Media: Technically Confirmed Criteria.docx|Technically Confirmed Criteria]] ''November 14, 2016''
* [[Profile: FDG-PET Whole Body]] ''First version of Profile, 2009 (currently inactive)''
+
*[[Media: Summary.docx| Summary of Changes to the FDG-PET/CT Profile]] ''November 14, 2016''
 +
 
 +
'''<font color=green>Recent updates from Dr. Kinahan for BC review:</font>
 +
*[[Media: QIBA_FDG-PET_Profile_v111-edits.doc|Updated QIBA FDG-PET Profile: FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy v111]] ''November 10, 2016''
 +
 
 +
 
 +
'''<font color=green>Recent updates from Dr. Turkington for BC review:</font>
 +
*[[Media: QIBA_FDG-PET_Profile_v110-edits.doc|Updated QIBA FDG-PET Profile v110 (edits shown), post Oct 7, 2016 call]]
 +
*[[Media: QIBA_FDG-PET_Profile_v110-clean.doc|Updated QIBA FDG-PET Profile v110 (clean version), post Oct 7, 2016 call]]
 +
*[[Media: scanner-checklist-table-v1.docx|QIBA FDG-PET Scanner Checklist, post Oct 7, 2016 call]]
 +
*[[Media: site-checklist-table-v3.docx|QIBA FDG-PET Site Checklist, post Oct 7, 2016 call]]
 +
 
 +
 
 +
Public Comment:
 +
 
 +
:[http://qibawiki.rsna.org/index.php?title=Work_Product_for_Review#QIBA_Profiles_for_Reference <font color=red>Public Comment Version and Feedback Process - FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy</font>]
 +
 
 +
*[[ARCHIVE]]
 +
 
 +
==UPICT Protocol Development==
 +
 
 +
*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Oncology FDG-PET CT Protocol, v2.5 Dec-2014]]
 +
*[[Media:UPICT Oncologic FDG-PETCTProtocol 5-20-14.pdf|UPICT Oncology FDG-PET CT Protocol 05-20-2014]]
 +
 
 +
*[[Media:UPICT Oncologic FDG-PETCTProtocol 6-07-13.pdf|UPICT Oncology FDG-PET CT Protocol 06-07-2013]]
 +
*[[Media:UPICT Oncologic FDG-PETCTProtocol 5-28-13.doc|UPICT Oncology FDG-PET CT Protocol 05-28-2013]]
 +
*[[Media:UPICT FDG Consolidated Statement post call 05032011-1.doc|UPICT Consolidated Statement-Post Call 05-03-2011]]
 +
 
 +
 
 +
==FDG-PET Reporting Standards Writing Group==
 +
 
 +
'''Problem Statement:'''
 +
• Gap between what is reported and what is needed for meta-analysis to determine value of quantitative imaging biomarkers
 +
• This is now established in the literature
 +
 
 +
'''Group members as of 5/27/2014:'''
 +
*Paul Kinahan, PhD  (Co-Chair)
 +
*Paul Marsden, PhD (Co-Chair)
 +
*Sally F. Barrington, MD
 +
*Anastasia Chalkidou, MD
 +
*Dominique Delbeke, MD, PhD
 +
*Constantine Gatsonis, PhD
 +
*Otto Hoekstra, MD, PhD
 +
*Erich Huang, PhD
 +
*Lisa McShane, PhD
 +
*Dan Sullivan, MD
 +
*Richard L. Wahl, MD
 +
 
 +
 
 +
[[Documents / Call Summaries]]
 +
 
 +
 
 +
 
 +
==Research Papers Analyzing FDG-PET Test-Retest Variability==
 +
 
 +
 
 +
* Hatt M, Cheze-Le Rest, C, Aboagye EO, et al.  Reproducibility of 18F-FDG  and 3'-Deoxy-3'-18F-Fluorothymidine PET Tumor Volume Measurements. ''The Journal of Nuclear Medicine''2010; 51(9):1368-1376. [http://jnm.snmjournals.org/content/51/9/1368.long]
 +
 
 +
* Kamibayashi T, Tsuchida T, Demura Y, et al.  Reproducibility of Semi-quantitative Parameters in FDG-PET Using Two Different PET Scanners: Influence of Attenuation Correction Method and Examination Interval.  ''Academy of Molecular Imaging'' 2008; 10:162-166.[http://www.springerlink.com/content/75860k16208wh2tt/]
 +
 
 +
* Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI Definition and Reconstruction Method on Quantitative Outcome and Applicability in a Response Monitoring Trial. ''European Journal of Nuclear Medicine and Molecular Imaging'' 2005; 32(3):294–301.[http://www.springerlink.com/content/79ajcfqdtmuj7gat/]
 +
 
 +
* Minn H, Zasadny KR, Quint LE, Wahl RL.  Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating 2-[F-18]-Fluoro-2-deoxy-D-glucose Uptake at PET1.  Radiology 1995; 196:167-173.[http://radiology.rsna.org/content/196/1/167.long]
 +
 
 +
* Nahmias C, Wahl LM.  Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors. ''The Journal of Nuclear Medicine'' 2008; 49(11):1804-1808. [http://jnm.snmjournals.org/content/49/11/1804.long]
 +
 
 +
* Nakamoto Y, Zasadny KR, Heikki M, Wahl RL.  Reproducibility of Common Semi-quantitative Parameters for Evaluating Lung Cancer Glucose Metabolism with Positron Emission Tomography Using 2-Deoxy-2-[18F] Fluoro-D-Glucose.  ''Molecular Imaging and Biology'' 2002; 4(2):171-178. [http://www.sciencedirect.com/science/article/pii/S153616320100004X]
 +
 
 +
* Velasquez, LM, Boellaard R, Kollia G, et al.  Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies. ''The Journal of Nuclear Medicine'' 2009;50:1646-1654. [http://jnm.snmjournals.org/content/50/10/1646.long]
 +
 
 +
* Weber WA, Ziegler SI, Thodtmann R, et al.  Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET. ''The Journal of Nuclear Medicine'' 1999; 40(11):1771-1777. [http://jnm.snmjournals.org/content/40/11/1771.long]
 +
 
  
 
==Working Documents and Reference Materials==
 
==Working Documents and Reference Materials==
 +
 +
*[http://www.sciencedirect.com/science/article/pii/S1550413116303606 QIBA collaborative manuscript on quantitative imaging of brown fat with PET/CT -  link to article]
 +
*[[Media: QIBA_FDG-PET_Profile_v104_post24Maycall.pdf|Updated QIBA FDG-PET Profile v104, post May 24, 2013 call]]
 +
*[[Media: QIBA_FDG-PET_Public Comment Feedback_v104_post24Maycall.pdf|Updated QIBA FDG-PET Public Comment Feedback v104, post May 24, 2013 call]]
 +
 +
*[http://radiology.rsna.org/content/196/1/167.full.pdf+html Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating FDG-PET]
 +
*[[Media:FDG-PET data warehouse use case and requirements_08FEb2012.doc|02.17.2012 QIBA FDG-PET Data Warehouse Use Case and Requirements]]
 +
*[[Agenda from 02.17.2012 FDG-PET Tech Committee Call]]
 
*[[Covariates Rationale]]
 
*[[Covariates Rationale]]
 
*[[Standardized Uptake Value (SUV)]]
 
*[[Standardized Uptake Value (SUV)]]
Line 35: Line 129:
  
 
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]
 
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]
 +
  
 
'''The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)'''
 
'''The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)'''
Line 64: Line 159:
  
 
==Slide Presentations==
 
==Slide Presentations==
 +
 +
*[[Media:NMCupdate.pdf|QIBA Steering Committee Meeting Presentation - Nuclear Medicine Modality Committee (January 2013)]]
 
*[[QIBA Informational Meeting (Dec 1st at RSNA 2008) - Slide Content Review]]
 
*[[QIBA Informational Meeting (Dec 1st at RSNA 2008) - Slide Content Review]]
 
*[[Media:Dr Frank Breakout + PETCT Tech Cmte 081204.ppt|QIBA Working Meeting (Dec 4th at RSNA 2008) - FDG-PET/CT Breakout Session Slide Deck]]
 
*[[Media:Dr Frank Breakout + PETCT Tech Cmte 081204.ppt|QIBA Working Meeting (Dec 4th at RSNA 2008) - FDG-PET/CT Breakout Session Slide Deck]]
Line 71: Line 168:
 
*[[Media:ProfilingSlides-ABuckler-20090331.pdf|QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)]]
 
*[[Media:ProfilingSlides-ABuckler-20090331.pdf|QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)]]
 
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]
 
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]
 +
 +
==QIBA Funded Projects==
 +
 +
====Round 1====
 +
 +
*[[VU University Medical Center, The Netherlands]]
 +
 +
*[[University of Washington]] - Digital Reference Object
 +
 +
*[[Johns Hopkins University School of Medicine]]
 +
 +
====Round 2====
 +
 +
*[[VU University Medical Center, The Netherlands, Round-2]]
 +
*[[Johns Hopkins University School of Medicine, Round-2]]
 +
*[[Dana-Farber Cancer Institute]]
 +
*[[Perlman Advisory Group]]
 +
 +
====Round 3====
 +
*[[Media:FDG-PET-CT Profile Field Test.pdf | Project (C) FDG-PET-CT Profile Field Test (Duke University)]]
 +
*[[Media:FDG-PET-CT DRO.pdf | Project (E) FDG-PET-CT Digital Reference Object (DRO) Extension (University of Washington)]]
 +
 +
====Round 4====
 +
*[[Media:FDG-PET-CT Profile Multi-Center Field Test.pdf | Project (R) FDG-PET-CT Profile Multi-Center Field Test (Duke University)]]
 +
 +
====Round 5====
 +
*[[Media:Biologic and Reader Repeatability of FDG and CT Volumetric Parameters.pdf | Project (B) Biologic and Reader Repeatability of FDG and CT Volumetric Parameters (ACRIN 6678 & MERCK) (Johns Hopkins University)]]
 +
 +
====Round 6====
 +
*[[Media:SUV Quantification with Point Spread Function PET Reconstruction.pdf | Project (R) SUV Quantification with Point Spread Function PET Reconstruction (Johns Hopkins University)]]
 +
 +
==Ideas for Profile version 2.0==
 +
 +
A collection area for ideas to include in the next version of the Profile
 +
 +
 +
A PET Physicist here had this feedback, which I think you will appreciate:
 +
 +
I wish there was a way to accentuate the difference between dose and activity. There is an important distinction with proper definitions.
 +
Activity is a measure of decay rate, dps, mCi, MBq, whatever units one prefers.
 +
Dose is a measure of energy deposits in matter. A complex phenomena measured in rem, Sv, whatever.

Latest revision as of 20:43, 5 November 2021

Co-chairs: Nathan C. Hall, MD, PhD; John Sunderland, PhD; Jeffrey T. Yap, PhD
RSNA Staff Support: Julie Lisiecki

Quantitative FDG-PET Biomarker Committee Mission

Mission: Foster adoption of pragmatic and cost effective standards for accurate and reproducible longitudinal quantitation of biologic parameters with clinical relevance and known sigma


Recent Meetings / Call Summaries


FDG-PET Call Summaries Archive

Nuclear Medicine Combined Biomarker Committee Calls for FDG-PET, Amyloid, SPECT


Profile Development

Technically Confirmed Profile and Supporting Documents:

Recent updates from Dr. Kinahan for BC review:


Recent updates from Dr. Turkington for BC review:


Public Comment:

Public Comment Version and Feedback Process - FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy

UPICT Protocol Development


FDG-PET Reporting Standards Writing Group

Problem Statement: • Gap between what is reported and what is needed for meta-analysis to determine value of quantitative imaging biomarkers • This is now established in the literature

Group members as of 5/27/2014:

  • Paul Kinahan, PhD (Co-Chair)
  • Paul Marsden, PhD (Co-Chair)
  • Sally F. Barrington, MD
  • Anastasia Chalkidou, MD
  • Dominique Delbeke, MD, PhD
  • Constantine Gatsonis, PhD
  • Otto Hoekstra, MD, PhD
  • Erich Huang, PhD
  • Lisa McShane, PhD
  • Dan Sullivan, MD
  • Richard L. Wahl, MD


Documents / Call Summaries


Research Papers Analyzing FDG-PET Test-Retest Variability

  • Hatt M, Cheze-Le Rest, C, Aboagye EO, et al. Reproducibility of 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET Tumor Volume Measurements. The Journal of Nuclear Medicine2010; 51(9):1368-1376. [1]
  • Kamibayashi T, Tsuchida T, Demura Y, et al. Reproducibility of Semi-quantitative Parameters in FDG-PET Using Two Different PET Scanners: Influence of Attenuation Correction Method and Examination Interval. Academy of Molecular Imaging 2008; 10:162-166.[2]
  • Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI Definition and Reconstruction Method on Quantitative Outcome and Applicability in a Response Monitoring Trial. European Journal of Nuclear Medicine and Molecular Imaging 2005; 32(3):294–301.[3]
  • Minn H, Zasadny KR, Quint LE, Wahl RL. Lung Cancer: Reproducibility of Quantitative Measurements for Evaluating 2-[F-18]-Fluoro-2-deoxy-D-glucose Uptake at PET1. Radiology 1995; 196:167-173.[4]
  • Nahmias C, Wahl LM. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors. The Journal of Nuclear Medicine 2008; 49(11):1804-1808. [5]
  • Nakamoto Y, Zasadny KR, Heikki M, Wahl RL. Reproducibility of Common Semi-quantitative Parameters for Evaluating Lung Cancer Glucose Metabolism with Positron Emission Tomography Using 2-Deoxy-2-[18F] Fluoro-D-Glucose. Molecular Imaging and Biology 2002; 4(2):171-178. [6]
  • Velasquez, LM, Boellaard R, Kollia G, et al. Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies. The Journal of Nuclear Medicine 2009;50:1646-1654. [7]
  • Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET. The Journal of Nuclear Medicine 1999; 40(11):1771-1777. [8]


Working Documents and Reference Materials


The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)

Please keep the following in mind:

The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):

  • Use of oral contrast is now excluded but will be allowed in the next version
  • We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)
  • There will be an upper limit for dosage
  • We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).
  • Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).
  • Various other minor edits/typos/changes

The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.

Submitted by Ronald Boellaard, PhD

Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD

Submitted by Eric S. Perlman, MD

Slide Presentations

QIBA Funded Projects

Round 1

Round 2

Round 3

Round 4

Round 5

Round 6

Ideas for Profile version 2.0

A collection area for ideas to include in the next version of the Profile


A PET Physicist here had this feedback, which I think you will appreciate:

I wish there was a way to accentuate the difference between dose and activity. There is an important distinction with proper definitions. Activity is a measure of decay rate, dps, mCi, MBq, whatever units one prefers. Dose is a measure of energy deposits in matter. A complex phenomena measured in rem, Sv, whatever.